Appendix – Supplementary file

This supplementary file is provided by the authors to give readers additional information about their study *"Patterns of end-of-life care among hospitalised patients with haematological malignancies"*.

Table A1 – Categorisation of haematological malignancies

Haematological disease	ICD-10 codes
Acute leukemia	C91.0, C92.0, C92.3, C92.4, C93.0, C94.0, C94.2, C95.0
Chronic lymphoid leukemia	C91.1
Chronic myeloid leukemia	C92.1, C92.2
Hodgkin's lymphoma	C81
Multiple myeloma	C90
Myelodysplastic syndromes	D46
Non-Hodgkin's lymphoma	C82, C83, C84, C85, C88.0

Table A2 – Sex- and age-standardized prevalence of comorbidities in hospitalized patients with haematological malignancies near the end of life

|	Total study population	Acute leukaemia	Chronic lymphoid leukaemia	Chronic myeloid leukaemia	Hodgkin's lymphoma	Multiple myeloma	Myelo-dysplastic syndromes	Non-Hodgkin's lymphoma
	n=46,629	*n=11,531*	*n=4,161*	*n=1,157*	*n=1,022*	*n=8,803*	*n=6,693*	*n=13,262*
Mean number of other chronic conditions								
Mean (SD)[a]	1.1 (1.2)	0.8 (1.0)	1.2 (1.2)	1.4 (1.4)	1.2 (1.3)	1.2 (1.2)	1.5 (1.4)	1.0 (1.1)
Prevalence of other chronic conditions (%)[b]								
Acute Myocardial Infarction	3.3%	2.5%	3.7%	6.3%	5.1%	3.0%	4.5%	3.2%
Heart Failure	25.8%	18.7%	28.5%	34.0%	31.9%	29.5%	36.7%	22.1%
Peripheral Vascular Disease	5.6%	3.9%	6.4%	9.7%	7.0%	4.2%	9.2%	5.4%
Cerebrovascular Accident	8.9%	9.1%	9.9%	13.3%	10.4%	7.1%	12.0%	7.5%
Dementia	7.6%	5.1%	9.4%	8.5%	8.9%	7.8%	10.7%	7.3%
Pulmonary Diseases	8.8%	6.2%	11.9%	11.4%	11.2%	8.3%	12.4%	8.2%
Connective Tissue Disorders	1.4%	1.1%	1.0%	1.7%	1.6%	0.9%	2.5%	1.4%
Peptic Ulcer	2.0%	0.9%	1.6%	1.7%	2.6%	2.1%	2.5%	2.7%
Liver diseases	4.3%	2.7%	3.8%	5.7%	4.5%	2.6%	9.2%	4.4%
Diabetes	15.6%	13.3%	17.9%	18.1%	16.1%	13.0%	20.1%	16.2%
Paraplegia	4.9%	2.5%	5.4%	5.6%	5.6%	5.4%	4.5%	6.6%
Renal failure	16.2%	8.4%	13.8%	19.6%	12.1%	30.0%	20.8%	12.3%
HIV	0.5%	0.1%	0.1%	0.2%	1.3%	0.3%	0.4%	1.2%

Sex- and age-standardized percentages, using the total study population as reference.
SD= standard deviation
[a] p<0.001 (Wilcoxon rank sum test)
[b] p<0.001 (Pearson's chi-square test)

Figure A1 - Change in treatment use over the course of the last 3 months of life of hospitalized patients with haematological malignancies

Legend figure A1: Sex- and age-standardized proportions, using the total study population as reference

Table A3 – Change in treatment use over the course of the last 3 months before death of hospitalized patients with haematological malignancies

	Total study population	Acute leukaemia	Chronic lymphoid leukaemia	Chronic myeloid leukaemia	Hodgkin's lymphoma	Multiple myeloma	Myelo-dysplastic syndromes	Non-Hodgkin's lymphoma
	n=46,629	*n=11,531*	*n=4,161*	*n=1,157*	*n=1,022*	*n=8,803*	*n=6,693*	*n=13,262*
	n (%)	n (%)[a]	n (%)[a]	n (%)[a]	n (%)[a]	n (%)[a]	n (%)[a]	n (%)[a]
Chemotherapy								
3rd month before death	11,071 (23.7)	2,563 (22.2)	746 (17.9)	92 (7.9)	323 (31.6)	2,516 (28.6)	670 (10.0)	3,948 (29.8)
2nd month before death	11,790 (25.3)	2,736 (23.7)	766 (18.4)	98 (8.5)	332 (32.5)	2,732 (31.0)	693 (10.4)	4,234 (31.9)
4th to 3rd weeks before death	9,353 (20.1)	2,389 (20.7)	561 (13.5)	84 (7.3)	248 (24.3)	2,075 (23.6)	519 (7.8)	3,289 (24.8)
2nd week before death	7,287 (15.6)	2,007 (17.4)	394 (9.5)	53 (4.6)	166 (16.2)	1,481 (16.8)	366 (5.5)	2,547 (19.2)
Last week before death	6,144 (13.2)	1,847 (16.0)	329 (7.9)	47 (4.0)	118 (11.6)	1,199 (13.6)	278 (4.2)	2,071 (15.6)
Blood transfusion								
3rd month before death	13,380 (28.7)	4,697 (40.7)	874 (21.0)	328 (28.3)	167 (16.3)	2,035 (23.1)	2,943 (44.0)	2,273 (17.1)
2nd month before death	17,220 (36.9)	5,945 (51.6)	1,117 (26.8)	412 (35.6)	226 (22.1)	2,764 (31.4)	3,483 (52.0)	3,223 (24.3)
4th to 3rd weeks before death	17,435 (37.4)	6,178 (53.6)	1,169 (28.1)	409 (35.3)	260 (25.5)	2,871 (32.6)	3,184 (47.6)	3,347 (25.2)
2nd week before death	16,478 (35.3)	5,748 (49.9)	1,161 (27.9)	373 (32.3)	242 (23.6)	2,747 (31.2)	2,977 (44.5)	3,233 (24.4)
Last week before death	16,832 (36.1)	5,861 (50.8)	1,266 (30.4)	421 (36.4)	277 (27.1)	2,733 (31.0)	3,030 (45.3)	3,256 (24.5)
Invasive ventilation								
3rd month before death	675 (1.4)	130 (1.1)	74 (1.8)	24 (2.1)	31 (3.0)	91 (1.0)	112 (1.7)	222 (1.7)
2nd month before death	1,564 (3.4)	339 (2.9)	178 (4.3)	57 (4.9)	53 (5.2)	221 (2.5)	312 (4.7)	448 (3.4)
4th to 3rd weeks before death	2,777 (6.0)	614 (5.3)	287 (6.9)	92 (7.9)	88 (8.6)	429 (4.9)	514 (7.7)	762 (5.7)
2nd week before death	3,675 (7.9)	780 (6.8)	390 (9.4)	135 (11.6)	125 (12.2)	577 (6.6)	680 (10.2)	1,025 (7.7)
Last week before death	5,610 (12.0)	1,167 (10.1)	680 (16.3)	214 (18.5)	193 (18.8)	889 (10.1)	1,026 (15.3)	1,532 (11.5)
Hemodynamic support								
3rd month before death	929 (2.0)	194 (1.7)	83 (2.0)	33 (2.9)	36 (3.5)	144 (1.6)	173 (2.6)	293 (2.2)
2nd month before death	1,924 (4.1)	430 (3.7)	205 (4.9)	64 (5.5)	57 (5.5)	294 (3.3)	366 (5.5)	540 (4.1)
4th to 3rd weeks before death	3,142 (6.7)	685 (5.9)	315 (7.6)	103 (8.9)	93 (9.1)	510 (5.8)	585 (8.7)	870 (6.6)
2nd week before death	4,099 (8.8)	856 (7.4)	414 (10.0)	147 (12.7)	132 (12.9)	684 (7.8)	754 (11.3)	1,147 (8.6)
Last week before death	6,281 (13.5)	1,281 (11.1)	723 (17.4)	244 (21.1)	212 (20.7)	1,032 (11.7)	1,131 (16.9)	1,724 (13)

[a] *Sex- and age-standardized values, using the total study population as reference*